Answer
The press release you quoted does not include any specifics about the vesting schedule or the exercise period for the non‑statutory stock option that Apyx Medical Corporation granted to John Featherstone.
The only information disclosed in the release is:
- Grant date: August 4 2025
- Number of shares covered: 100,000 common‑stock shares
- Recipient: John Featherstone, Vice President, North American Sales
- Nature of the award: a non‑statutory (i.e., “non‑qualified”) stock option issued as a material inducement under Nasdaq Listing Rule 5635(c)(4).
All other terms—such as when the option begins to vest (e.g., immediately, on a set schedule, or upon achievement of certain milestones) and the length of the post‑grant exercise window (e.g., 5 years, 10 years, or any other period)—were not provided in the news item.
How to Find the Missing Details
SEC Filings (e.g., Form 8‑K, Form 4, or a proxy statement):
Companies typically disclose the full terms of an employee‑stock‑option grant in the accompanying exhibit to a Form 8‑K filing or in a subsequent proxy statement/Form DEF 14A. Look for the filing dated around August 4‑5 2025 on the SEC’s EDGAR system.Company’s Equity‑Compensation Plan Documents:
The grant is likely made under Apyx’s existing “Stock Incentive Plan” (or similarly named plan). Those plan documents usually outline default vesting and exercise‑period provisions for non‑statutory options, unless the board specifically amends them for a particular award.Contact Investor Relations:
If the SEC filings do not yet contain the details, a request to Apyx’s Investor Relations team can clarify the vesting and exercise terms.
Typical Industry Practices (for context)
While we cannot assert that Apyx follows any of these, many companies structure non‑statutory inducement options in one of the following ways:
| Vesting Schedule | Common Features |
|---|---|
| Immediate vesting | The option is fully exercisable on the grant date (or shortly thereafter). |
| Time‑based vesting | E.g., 25 % of the option vests each year over a 4‑year period. |
| Performance‑based vesting | Vesting tied to achievement of sales, revenue, or other operational milestones. |
| Hybrid | A combination of time‑ and performance‑based criteria. |
| Exercise Period | Common Features |
|---|---|
| Standard term | 5‑10 years from the grant date, after which the option expires if not exercised. |
| Post‑termination exercise (PTE) window | Often 90 days after termination of employment, but can be longer for senior executives. |
| Early‑exercise provisions | Some plans allow the holder to exercise before full vesting (subject to “early‑exercise” tax considerations). |
If Apyx’s grant follows a “typical” structure, you might expect a 5‑year term with full vesting either immediately or over a multi‑year schedule. However, without the exact language from the company’s filing or the award agreement, any such description would be speculative.
Bottom Line
- The press release does not specify the vesting dates or the exercise period.
- To obtain the definitive answer, you’ll need to review Apyx’s SEC filings (e.g., the Form 8‑K filed around August 4‑5 2025) or the company’s equity‑compensation plan documents.
If you locate those filings and still need help interpreting the language, feel free to share the relevant excerpts and I can walk you through the details.